title: The prevalence of weight concerns in a smoking abstinence clinical trial.
abstract: Recent research has demonstrated there is a high prevalence of weight concerns in smokers and that smokers with weight concerns may respond poorly to treatment for tobacco dependence. Most studies have focused only on females or have consisted of small samples. In this study of a 12-week randomized trial of nicotine inhaler, bupropion or both for smoking cessation, 50% of the 1012 female smokers and 26% of the 680 male smokers, at study entry, were weight concerned. In examining the impact of weight concerns on the 12-week point-prevalence smoking abstinence, 26% of non-weight-concerned smokers quit smoking compared to 22% of weight-concerned smokers (p=0.06). This study, which includes a large sample of both genders, provides further evidence that approximately half of females who are seeking smoking cessation treatment are weight concerned and that one quarter of male smokers are weight concerned. Additionally, being weight concerned may impact the short-term success rates of stopping smoking using pharmacotherapy.
authors.affiliation: Mayo Clinic - Mayo Building-W11, 200 First Street, SW, Rochester, MN 55905, USA. Clark.matthew@mayo.edu
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Clark
authors.forename: Richard D
authors.initials: RD
authors.lastname: Hurt
authors.forename: Ivana T
authors.initials: IT
authors.lastname: Croghan
authors.forename: Christi A
authors.initials: CA
authors.lastname: Patten
authors.forename: Paul
authors.initials: P
authors.lastname: Novotny
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: Shaker R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: Gary A
authors.initials: GA
authors.lastname: Croghan
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Wos
authors.forename: Kendrith M
authors.initials: KM
authors.lastname: Rowland
authors.forename: Albert
authors.initials: A
authors.lastname: Bernath
authors.forename: Roscoe F
authors.initials: RF
authors.lastname: Morton
authors.forename: Sachdex P
authors.initials: SP
authors.lastname: Thomas
authors.forename: Loren K
authors.initials: LK
authors.lastname: Tschetter
authors.forename: Stewart
authors.initials: S
authors.lastname: Garneau
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Stella
authors.forename: Larry P
authors.initials: LP
authors.lastname: Ebbert
authors.forename: Donald B
authors.initials: DB
authors.lastname: Wender
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001828:Body Image; D001835:Body Weight; D016642:Bupropion / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D012907:Smoking / Q000188:drug therapy / Q000523:psychology*; D016540:Smoking Cessation / Q000379:methods / Q000523:psychology*; D016896:Treatment Outcome; D014481:United States
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018722:Nicotinic Agonists; D016642:Bupropion; D009538:Nicotine